[
  {
    "content": "Volume 1, Issue 2, March - April 2010; Article 019 ISSN 0976 - 044X CLINICAL TRIAL: A REVIEW S. B. Thorat*, S. K. Banarjee, D. D. Gaikwad, S. L. Jadhav, R. M. Thorat Vishal Institute of Pharmaceutical Education And Research, Ale, Pune-412411. *E-mail : rupali.78@rediffmail.com ABSTRACT A clinical trial is a research study in human volunteers to answer specific health questions. Carefully conducted clinical trials are fastest and safest way to find treatment that work in people and way to improve health. Investigational trials determine whether experimental",
    "doc_id": "doc_019",
    "page": 1
  },
  {
    "content": "treatment or new ways of using known therapies are safe and effective under controlled environment. Observational trials address health issues in large groups of people or population in natural settings. Clinical trials aim to measure therapeutic effectiveness and constitute an important and highly specialized form of biological assay. In phase I pharmacokinetics, safety, gross effects are studied on human volunteers, by clinical pharmacologists. If the drug passes the test, it enters phase II testings, where pharmacokinetics, safety, therapeutic",
    "doc_id": "doc_019",
    "page": 1
  },
  {
    "content": "efficiency are studied on selected patients by clinical pharmacologist, if passes hundreds of selected patients are now studied, primarily for safety and therapeutic effectiveness by clinical investigators in phase III. If this is passed the drug is now approved and marketed. Even after marketing, physicians from various hospitals and clinics send their opinion about the drug, regarding ADR, efficacy in phase IV. Keywords: Clinical Trials, Preclinical Studies, Clinical studies, NDA. INTRODUCTION",
    "doc_id": "doc_019",
    "page": 1
  },
  {
    "content": "A clinical trial is a research study that tests a new medical treatment or a new way of using an existing treatment to see if it will be a better way to prevent and screen for diagnose or treat a disease\" For any new drug to enter in clinical trial, it must pass preclinical studies. Preclinical studies involve in vitro (i.e. test-tube or Laboratory) studies and trials on animal populations. Wide range of dosages of the study drug is given to animal subjects or to an in-vitro substrate in order to obtain preliminary",
    "doc_id": "doc_019",
    "page": 1
  },
  {
    "content": "efficacy, toxicity and pharmacokinetic information2. PHASES OF CLINICAL TRIAL PRE-CLINICAL RESEARCH E CLINICAL STUDIES NDA REVIEW PHASE 1 E PHASE 2 SYNTHESIS AND PURIFICATION PHASE 3 ... ACCELERATED: DEVELOPMENT/REVIEW ANIMAL TESTING ... E TREATMENT IND SHORT-TERM PARALLEL TRACK LONG-TERM INSTITUTIONAL REVIEW BOARDS INDUSTRY TIME FDA TIME IND SUBMITTED AA NDA SUBMITTED REVIEW DECISION SPONSOR/FDA MEETINGS ENCOURAGED EARLY ACCESS: E SUBPART E ADVISORY COMMITTEES SPONSOR ANSWERS ANY QUESTIONS FROM REVIEW",
    "doc_id": "doc_019",
    "page": 1
  },
  {
    "content": "Before pharmaceutical companies start clinical trials on a drug, they conduct extensive pre-clinical studies3. Pre-clinical studies Pre-clinical studies involve in vitro (i.e., test tube or laboratory) studies and trials on animal populations. Wide- ranging dosages of the study drug are given to the animal subjects or to an in-vitro substrate in order to obtain preliminary efficacy, toxicity and pharmacokinetic information and to assist pharmaceutical companies in deciding whether it is worthwhile to go ahead with further",
    "doc_id": "doc_019",
    "page": 1
  },
  {
    "content": "testing. Phase 0 Phase 0 is a recent designation for exploratory, first-in- human trials conducted in accordance with the U.S. Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies Phase 0 trials are designed to speed up the development of promising drugs or imaging agents by establishing very early on whether the drug or agent behaves in human subjects as was anticipated from preclinical studies. Distinctive features of Phase 0 trials include the administration of single sub",
    "doc_id": "doc_019",
    "page": 1
  },
  {
    "content": "therapeutic doses of the study drug to a small number of subjects (10 to 15) to gather preliminary data on the agent's pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug works in the body). Phase I Phase I trials are the first stage of testing in human subjects. Normally, a small (20-80) group of healthy volunteers will be selected. This phase includes trials designed to assess the safety (pharmacovigilance), tolerability, pharmacokinetics, and pharmacodynamics of",
    "doc_id": "doc_019",
    "page": 1
  },
  {
    "content": "a drug. These trials are often conducted in an inpatient clinic, where the subject can be observed by full-time staff. The subject who receives the drug is usually observed until several half-lives of the drug have passed. International Journal of Pharmaceutical Sciences Review and Research Available online at www.globalresearchonline.net Page 101",
    "doc_id": "doc_019",
    "page": 1
  },
  {
    "content": "Volume 1, Issue 2, March - April 2010; Article 019 ISSN 0976 - 044X Phase I trials also normally include dose-ranging, also called dose escalation, studies so that the appropriate dose for therapeutic use can be found. The tested range of doses will usually be a fraction of the dose that causes harm in animal testing. Phase I trials most often include healthy volunteers. However, there are some circumstances when real patients are used, such as patients who have end-stage disease and lack other treatment options. This exception to",
    "doc_id": "doc_019",
    "page": 2
  },
  {
    "content": "the rule most often occurs in oncology (cancer) and HIV drug trials. Volunteers are paid an inconvenience fee for their time spent in the volunteer centre. Pay ranges from a small amount of money for a short period of residence, to a larger amount of up to approx Â£4000 depending on length of participation. There are different kinds of Phase I trials: 1. SAD Single Ascending Dose studies are those in which small groups of subjects are given a single dose of the drug while they are observed and tested for a period of time. If",
    "doc_id": "doc_019",
    "page": 2
  },
  {
    "content": "they do not exhibit any adverse side effects, and the pharmacokinetic data is roughly in line with predicted safe values, the dose is escalated, and a new group of subjects is then given a higher dose. This is continued until pre- calculated pharmacokinetic safety levels are reached, or intolerable side effects start showing up at which point the drug is said to have reached the Maximum tolerated dose (MTD). 2. MAD Multiple Ascending Dose studies are conducted to better understand the pharmacokinetics & pharmacodynamics of",
    "doc_id": "doc_019",
    "page": 2
  },
  {
    "content": "multiple doses of the drug. Phase II Once the initial safety of the study drug has been confirmed in Phase I trials, Phase II trials are performed on larger groups (20-300) and are designed to assess how well the drug works, as well as to continue Phase I safety assessments in a larger group of volunteers and patients. When the development process for a new drug fails, this usually occurs during Phase II trials when the drug is discovered not to work as planned, or to have toxic effects. Phase II studies are sometimes divided into Phase IIA and",
    "doc_id": "doc_019",
    "page": 2
  },
  {
    "content": "Phase IIB. Phase IIA is specifically designed to assess dosing requirements (how much drug should be given), whereas Phase IIB is specifically designed to study efficacy (how well the drug works at the prescribed dose(s)). Some trials combine Phase I and Phase II, and test both efficacy and toxicity. Phase III Phase III studies are randomized controlled multicenter trials on large patient groups (300-3,000 or more depending upon the disease/medical condition studied) and are aimed at being the definitive assessment of how",
    "doc_id": "doc_019",
    "page": 2
  },
  {
    "content": "effective the drug is, in comparison with current 'gold standard' treatment. Because of their size and comparatively long duration, Phase III trials are the most expensive, time-consuming and difficult trials to design and run, especially in therapies for chronic medical conditions. It is common practice that certain Phase III trials will continue while the regulatory submission is pending at the appropriate regulatory agency. While not required in all cases, it is typically expected that there be at least two successful Phase III trials,",
    "doc_id": "doc_019",
    "page": 2
  },
  {
    "content": "demonstrating a drug's safety and efficacy, in order to obtain approval from the appropriate regulatory agencies (FDA (USA), TGA (Australia), EMEA (European Union), etc.). Once a drug has proved satisfactory after Phase III trials, the trial results are usually combined into a large document containing a comprehensive description of the methods and results of human and animal studies, manufacturing procedures, formulation details, and shelf life. This collection of information makes up the \"regulatory submission\" that is provided for review to the",
    "doc_id": "doc_019",
    "page": 2
  },
  {
    "content": "appropriate regulatory authoritiesin different countries. Most drugs undergoing Phase III clinical trials can be marketed under FDA norms with proper recommendations and guidelines, but in case of any adverse effects being reported anywhere, the drugs need to be recalled immediately from the market. While most pharmaceutical companies refrain from this practice, it is not abnormal to see many drugs undergoing Phase III clinical trials in the market. Phase IV Phase IV trial is also known as Post Marketing",
    "doc_id": "doc_019",
    "page": 2
  },
  {
    "content": "Surveillance Trial. Phase IV trials involve the safety surveillance (pharmacovigilance) and ongoing technical support of a drug after it receives permission to be sold. Phase IV studies may be required by regulatory authorities or may be undertaken by the sponsoring company for competitive (finding a new market for the drug) or other reasons (for example, the drug may not have been tested for interactions with other drugs, or on certain population groups such as pregnant women, who are unlikely to",
    "doc_id": "doc_019",
    "page": 2
  },
  {
    "content": "subject themselves to trials). The safety surveillance is designed to detect any rare or long-term adverse effects over a much larger patient population and longer time period than was possible during the Phase I-III clinical trials. Harmful effects discovered by Phase IV trials may result in a drug being no longer sold, or restricted to certain uses: recent examples involve cerivastatin (brand names Baycol and Lipobay), troglitazone (Rezulin) and rofecoxib (Vioxx)2. INVESTIGATIONAL NEW DRUG (IND)",
    "doc_id": "doc_019",
    "page": 2
  },
  {
    "content": "CLINICAL TRIAL EXCEPTION (CTX) / CLINICAL TRIAL AUTHORIZATION (CTA) APPLICATION / INDs (in the U.S.), CTXs (in the U.K.) and CTAs (in Australia) are examples of requests submitted to appropriate regulatory authorities for permission to conduct investigational research. This research can include testing of a new dosage form or new use of a drug already approved to be marketed. In addition to obtaining permission from appropriate regulatory authorities, an Institutional or Independent Review Board (IRB) OR Ethical Advisory Board must",
    "doc_id": "doc_019",
    "page": 2
  },
  {
    "content": "approve the protocol for testing as well as the informed consent documents that volunteers sign prior to International Journal of Pharmaceutical Sciences Review and Research Available online at www.globalresearchonline.net Page 102",
    "doc_id": "doc_019",
    "page": 2
  }
]